CLPT:NSD-ClearPoint Neuro, Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 23.72

Change

+0.24 (+1.02)%

Market Cap

USD 0.47B

Volume

0.34M

Average Target Price

USD 22.38 (-5.67%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for insertion of catheters, electrodes, and laser fibers to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to allow catheter-based minimally invasive procedures in the heart to be performed in an MRI suite. The company has a license agreements with The Johns Hopkins University; development agreement with Mayo Clinic to design and develop MRI-guided therapies for stroke; and a collaborative license and co-development agreement with Clinical Laserthermia Systems AB. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was founded in 1998 and is headquartered in Irvine, California. Address: 5 Musick, Irvine, CA, United States, 92618

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-02 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

-1.90 (-0.34%)

USD44.93B 25.33 113.18
PODD Insulet Corporation

-4.35 (-1.61%)

USD17.86B 2,702.60 156.24
ABMD Abiomed, Inc

+1.05 (+0.32%)

USD14.71B 74.15 57.21
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

-0.19 (-0.30%)

USD9.54B 61.10 26.86
TNDM Tandem Diabetes Care, Inc

-2.29 (-2.39%)

USD5.99B N/A N/A
IART Integra LifeSciences Holdings ..

-0.17 (-0.24%)

USD5.86B 44.22 24.73
SDC SmileDirectClub, Inc

-0.15 (-1.29%)

USD4.48B N/A N/A
AHCO AdaptHealth Corp

+0.18 (+0.56%)

USD4.17B -99,999.99 40.71
SWAV ShockWave Medical, Inc

-1.90 (-1.55%)

USD4.00B N/A N/A

ETFs Containing CLPT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 71.51% 84% B 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 71.51% 84% B 92% A-
Trailing 12 Months  
Capital Gain 368.77% 99% A+ 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 368.77% 99% A+ 95% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 10.37% 35% F 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.37% 35% F 75% C
Risk Return Profile  
Volatility (Standard Deviation) 59.91% 23% F 6% F
Risk Adjusted Return 17.30% 27% F 41% F
Market Capitalization 0.47B 56% F 49% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 89% B+ 99% A+
Price/Book Ratio 2,791.98 1% F 0% N/A
Price / Cash Flow Ratio -164.34 96% A 96% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -222.37% 11% F 5% F
Return on Invested Capital -78.86% 31% F 12% F
Return on Assets -19.06% 35% F 20% F
Debt to Equity Ratio 45.19% 50% F 46% F
Technical Ratios  
Short Ratio 0.61 74% C 72% C-
Short Percent 1.25% 91% A- 75% C
Beta 1.07 51% F 55% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector